Valuation: Roche Holding AG

Market Cap 293B 363B 314B 269B 506B 34,547B 514B 3,440B 1,350B 17,316B 1,363B 1,333B 57,245B P/E 2026 *
20.5x
P/E 2027 * 18.2x
Enterprise Value 304B 376B 326B 279B 525B 35,827B 533B 3,568B 1,400B 17,957B 1,414B 1,383B 59,366B EV / Sales 2026 *
4.85x
EV / Sales 2027 * 4.54x
Free-Float
88.78%
Yield 2026 *
2.72%
Yield 2027 * 2.78%
Manager TitleAgeSince
Chief Executive Officer 51 2023-03-14
Director of Finance/CFO 59 2011-06-05
Chief Operating Officer - 2025-09-30
Director TitleAgeSince
Director/Board Member 68 1995-12-31
Chairman 59 2023-03-14
Director/Board Member 73 2015-03-02
Change 5-day change 1-year change 3-year change Capi.($)
-1.35%+2.01% - - 363B
-0.52%+3.21%+89.52%+125.32% 1,057B
+0.88%+1.13%+49.56%+49.79% 625B
+0.89%-1.95%+24.23%+63.19% 435B
+0.35%+3.51%+49.61%+38.07% 363B
-0.28%+0.92%+30.85%+38.71% 296B
+0.07%+3.53%+7.88%+6.67% 249B
+1.51%+6.69%+42.58%+58.47% 222B
-0.99%+0.02%-6.28%-51.55% 209B
+1.80%+2.30%+11.56%+66.16% 165B
Average +0.23%+0.94%+33.28%+43.87% 402.31B
Weighted average by Cap. +0.10%+1.33%+48.41%+63.84%

Financials

2026 *2027 *
Net sales 62.64B 77.55B 67.08B 57.47B 108B 7,381B 110B 735B 288B 3,699B 291B 285B 12,230B 65.47B 81.05B 70.11B 60.06B 113B 7,714B 115B 768B 301B 3,866B 304B 298B 12,782B
Net income 14.51B 17.96B 15.53B 13.31B 25.03B 1,709B 25.43B 170B 66.8B 857B 67.44B 65.96B 2,832B 16.33B 20.22B 17.49B 14.98B 28.18B 1,924B 28.63B 192B 75.21B 964B 75.93B 74.26B 3,189B
Net Debt 10.87B 13.45B 11.64B 9.97B 18.75B 1,280B 19.05B 127B 50.04B 642B 50.52B 49.41B 2,121B 4.02B 4.98B 4.3B 3.69B 6.94B 474B 7.05B 47.16B 18.51B 237B 18.69B 18.28B 785B
Logo Roche Holding AG
Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
AA